Surface-adsorbed reverse micelle-loaded solid self-nanoemulsifying drug delivery system of talinolol
The aim of present investigation was to develop surface-adsorbed reverse-micelle-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) of talinolol in order to enhance its in vitro dissolution rate, which in turn enhance the bioavailability. SNEDDS were prepared using aqueous phase titration method. Thermodynamically stable formulations were characterized in terms of droplet size, viscosity, % transmittance, drug content and surface morphology. Low cost acid-treated coffee husk was used as an effective biosorbent for preparation of solid SNEDDS. Developed SNEDDS were subjected to in vitro drug release/dissolution studies. In vitro drug release studies showed 99.6% release of talinolol from optimized solid SNEDDS TS3 after 120 min of study. The results of solubility studies showed 4849.5-folds enhancement in solubility of talinolol from optimized SNEDDS as compared to its aqueous solubility.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Pharmaceutical development and technology - 21(2016), 2 vom: 14. März, Seite 131-9 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shakeel, Faiyaz [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 18.10.2016 Date Revised 08.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3109/10837450.2014.971379 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM242814204 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM242814204 | ||
| 003 | DE-627 | ||
| 005 | 20231224131214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3109/10837450.2014.971379 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0809.xml |
| 035 | |a (DE-627)NLM242814204 | ||
| 035 | |a (NLM)25318634 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shakeel, Faiyaz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Surface-adsorbed reverse micelle-loaded solid self-nanoemulsifying drug delivery system of talinolol |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 18.10.2016 | ||
| 500 | |a Date Revised 08.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The aim of present investigation was to develop surface-adsorbed reverse-micelle-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) of talinolol in order to enhance its in vitro dissolution rate, which in turn enhance the bioavailability. SNEDDS were prepared using aqueous phase titration method. Thermodynamically stable formulations were characterized in terms of droplet size, viscosity, % transmittance, drug content and surface morphology. Low cost acid-treated coffee husk was used as an effective biosorbent for preparation of solid SNEDDS. Developed SNEDDS were subjected to in vitro drug release/dissolution studies. In vitro drug release studies showed 99.6% release of talinolol from optimized solid SNEDDS TS3 after 120 min of study. The results of solubility studies showed 4849.5-folds enhancement in solubility of talinolol from optimized SNEDDS as compared to its aqueous solubility | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Biosorption | |
| 650 | 4 | |a Talinolol | |
| 650 | 4 | |a coffee husk | |
| 650 | 4 | |a dissolution | |
| 650 | 4 | |a self-nanoemulsifying drug delivery system | |
| 650 | 7 | |a Drug Carriers |2 NLM | |
| 650 | 7 | |a Emulsions |2 NLM | |
| 650 | 7 | |a Excipients |2 NLM | |
| 650 | 7 | |a Micelles |2 NLM | |
| 650 | 7 | |a Propanolamines |2 NLM | |
| 650 | 7 | |a Surface-Active Agents |2 NLM | |
| 650 | 7 | |a talinolol |2 NLM | |
| 650 | 7 | |a 3S82268BKG |2 NLM | |
| 700 | 1 | |a Haq, Nazrul |e verfasserin |4 aut | |
| 700 | 1 | |a Alanazi, Fars K |e verfasserin |4 aut | |
| 700 | 1 | |a Alsarra, Ibrahim A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical development and technology |d 1998 |g 21(2016), 2 vom: 14. März, Seite 131-9 |w (DE-627)NLM094740194 |x 1097-9867 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2016 |g number:2 |g day:14 |g month:03 |g pages:131-9 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3109/10837450.2014.971379 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2016 |e 2 |b 14 |c 03 |h 131-9 | ||